Last updated on December 2019

An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)


Brief description of study

The purpose of this study is to assess the objective response rate of parsaclisib treatment in subjects with relapsed or refractory follicular lymphoma.

Clinical Study Identifier: NCT03126019

Find a site near you

Start Over